Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Mary B. Daly(Fox Chase Cancer Center), Mary A. Dwyer(National Comprehensive Cancer Network), Matthew B. Yurgelun(Dana-Farber Cancer Institute), Gwen Reiser(University of California San Diego), Patricia Dickson(Washington University in St. Louis), Jennifer K. Litton(The University of Texas MD Anderson Cancer Center), Christine Laronga(Moffitt Cancer Center), Holly J. Pederson(Cleveland Clinic), Jeffrey N. Weitzel(Cancer Genetics (United States)), Susan Darlow(National Comprehensive Cancer Network), Tuya Pal(Vanderbilt University Medical Center), Carolyn S. Menendez(Memorial Sloan Kettering Cancer Center), Kari B. Wisinski(University of Wisconsin Carbone Cancer Center), Rebecca Shatsky(University of California San Diego), Michael P. Berry(St. Jude Children's Research Hospital), Kristen M. Shannon(Massachusetts General Hospital), Leigha Senter-Jamieson(City Of Hope National Medical Center), Ahmed Elkhanany(University of Alabama at Birmingham), Wendy Kohlmann(University of Utah), Susan M. Domchek(University City Science Center), Allison W. Kurian(Stanford University), Sofía D. Merajver(University of Michigan), Myra Wick(WinnMed), Saundra S. Buys(University of Utah), Beth Y. Karlan(University of California, Los Angeles), Mollie L. Hutton(Roswell Park Comprehensive Cancer Center), Kala Visvanathan(Johns Hopkins University), Michael Goggins(Johns Hopkins University), Catherine Klein(University of Utah), Susan Friedman(Facing Our Risk of Cancer Empowered), Kenneth Offit(Memorial Sloan Kettering Cancer Center), Seema Khan(University of Colorado Cancer Center), Julie Mak(University of Michigan)
Journal of the National Comprehensive Cancer Network
January 6, 2021
Cited by 1,114


Related Papers